Kailera Therapeutics has filed for an initial public offering (IPO), ​hoping to whet investor appetites with its pipeline of drug candidates for weight loss. Waltham, Massachusetts-based Kailera has ...

The EMA's human medicines committee has recommended approval of Amgen's bispecific T-cell engager (BiTE) – Imdylltra – as a second-line treatment option for extensive-stage small cell lung cancer ...

A major UK-led study has found that undiagnosed heart failure (HF) can be detected in people with high-risk diabetes using a simple, community-based care pathway. The TARTAN-HF trial, run by the ...

Recordati has received an unsolicited takeover offer from private equity group CVC Capital Partners that, if completed, would ...

Top-line results from the OBERON and TITANIA trials showed that tozorakimab reduced the annualised rate of moderate-to-severe ...

At its second attempt, Rocket Pharma has won FDA approval for its gene therapy for severe leukocyte adhesion deficiency type ...

Insilico Medicines has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115 million upfront payment. The agreement – which could be worth as much ...

With the ink barely dry on one takeover agreement, Novartis has signed another, promising to pay up to $2 billion to acquire ...

Karyopharm is hoping to broaden the label for its first-in-class blood cancer therapy Xpovio to include myelofibrosis, even ...

Novo Nordisk has reported the first mid-stage clinical data with its triple G agonist for diabetes in China, as it starts an ...

MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer, ...

"Screening is typically recommended for patients with confirmed liver cirrhosis or severe liver disease, since many cases of ...